- Stocks
- Healthcare
- NASDAQ: INCY

Price (delayed)

$53.22

Market cap

$11.95B

P/E Ratio

19.93

Dividend/share

N/A

EPS

$2.67

Enterprise value

$8.77B

Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware. The company was founded in Palo Alto, California in 1991 and went public in 1993. Incyte has one drug,

INCY's net income has soared by 75% year-on-year and by 41% since the previous quarter

INCY's EPS has soared by 75% YoY and by 41% QoQ

The company's quick ratio rose by 6% YoY but it fell by 4.3% QoQ

The debt is up by 2.1% since the previous quarter

What are the main financial stats of INCY

Market
Valuations
Earnings

Shares outstanding

224.53M

Market cap

$11.95B

Enterprise value

$8.77B

Price to earnings (P/E)

19.93

Price to book (P/B)

2.3

Price to sales (P/S)

3.22

EV/EBIT

10.48

EV/EBITDA

9.53

EV/Sales

2.37

Revenue

$3.7B

EBIT

$836.77M

EBITDA

$919.43M

Free cash flow

$464M

Per share
Balance sheet
Liquidity

EPS

$2.67

Free cash flow per share

$2.07

Book value per share

$23.16

Revenue per share

$16.53

TBVPS

$29.08

Total assets

$6.78B

Total liabilities

$1.59B

Debt

$32.6M

Equity

$5.19B

Working capital

$3.41B

Debt to equity

0.01

Current ratio

3.75

Quick ratio

3.55

Net debt/EBITDA

-3.46

Margins
Efficiency
Dividend

EBITDA margin

24.9%

Gross margin

93.1%

Net margin

16.2%

Operating margin

16.8%

Return on assets

9.5%

Return on equity

12.4%

Return on invested capital

46.1%

Return on capital employed

15.1%

Return on sales

22.6%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Incyte stock price performed over time

Intraday

-0.39%

1 week

-3.76%

1 month

-8.82%

1 year

-28.56%

YTD

-15.24%

QTD

-6.58%

How have Incyte's revenue and profit performed over time

Revenue

$3.7B

Gross profit

$3.44B

Operating income

$620.53M

Net income

$597.6M

Gross margin

93.1%

Net margin

16.2%

INCY's net income has soared by 75% year-on-year and by 41% since the previous quarter

The net margin has soared by 62% year-on-year and by 37% since the previous quarter

Incyte's operating income has increased by 23% from the previous quarter and by 7% YoY

INCY's operating margin is up by 21% since the previous quarter

What is Incyte's growth rate over time

What is Incyte stock price valuation

P/E

19.93

P/B

2.3

P/S

3.22

EV/EBIT

10.48

EV/EBITDA

9.53

EV/Sales

2.37

INCY's EPS has soared by 75% YoY and by 41% QoQ

INCY's P/E is 44% below its last 4 quarters average of 35.4

The stock's price to book (P/B) is 58% less than its 5-year quarterly average of 5.5 and 23% less than its last 4 quarters average of 3.0

INCY's equity is up by 19% year-on-year and by 5% since the previous quarter

INCY's P/S is 48% below its 5-year quarterly average of 6.2 and 20% below its last 4 quarters average of 4.0

Incyte's revenue has increased by 9% YoY and by 2.4% from the previous quarter

How efficient is Incyte business performance

INCY's return on assets has surged by 51% year-on-year and by 36% since the previous quarter

The ROE has soared by 51% YoY and by 35% from the previous quarter

INCY's ROS is up by 44% YoY and by 26% QoQ

The ROIC has increased by 38% YoY and by 19% from the previous quarter

What is INCY's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for INCY.

How did Incyte financials performed over time

Incyte's total assets has increased by 16% YoY and by 6% from the previous quarter

INCY's total liabilities is up by 9% since the previous quarter and by 8% year-on-year

The debt is 99% smaller than the equity

INCY's equity is up by 19% year-on-year and by 5% since the previous quarter

The debt is up by 2.1% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.